Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Metformin, a synthetic dimethyl biguanide, has been in clinical use for over 55 years, and today is considered the first-choice drug for the treatment of type 2 diabetes used by an estimated 125 million people worldwide. Metformin is orally effective, not metabolized, excreted unchanged by the kidney, relatively free of side effects and well tolerated by the majority of patients. Of importance is that the United Kingdom Prospective Diabetes Study 20-year study of type 2 diabetics, completed in 1998, compared patients treated with insulin, sulfonylureas and metformin and concluded that metformin provided vascular protective actions. Cardiovascular disease is the primary basis for the high morbidity and mortality that is associated with diabetes and that metformin proved to be protective resulted in a dramatic increase in its use. The vascular protective actions of metformin are thought to be secondary to the antihyperglycaemic effects of metformin that are mediated via activation of AMP kinase and subsequent inhibition of hepatic gluconeogenesis, fatty acid oxidation as well as an insulin sensitizing action in striated muscle and adipose tissue. As reflected by a number of clinical studies, patients treated with metformin also have improvement in endothelial function as measured by the use of plethysmography and measurement of flow-mediated vasodilatation. These data as well as data from animal studies are supportive that metformin has a direct protective action on the vascular endothelium. In this review article, we discuss the pharmacology of metformin and critique the literature as to its cellular sites and mechanism(s) of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 2×
“In addition, there is considerable interest in the potential use of metformin in the prevention and treatment of various forms of cancer (Evans et al. 2005) with several putative mechanisms proposed for the latter including a reduction in the generation of reactive oxygen species (ROS) secondarily…”
BackgroundOWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 3×
“…is a strong base and the pH gradient in mitochondria would serve to oppose accumulation, although, it should be noted that as metformin exists as a cation at physiological pH it has been argued that the mitochondrial membrane potential would promote entry (Sch€afer 1980, Owen et al. 2000).”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Kinaan, M., Ding, H., & Triggle, C. R. (2015) · Medical Principles and Practice · doi:10.1159/000381643 · Cited by 1,515
Self-citationMetformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Metformin improves healthspan and lifespan in mice
Martin-Montalvo, A., Mercken, E. M., Mitchell, S. J., Palacios, H. H., Mote, P. L., Scheibye-Knudsen, M., Gomes, A. P., Ward, T. M., Minor, R. K., Blouin, M.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3192 · Cited by 1,445
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399 · cited 2×
“Two independent reports in 2000 (El-Mir et al. 2000, Owen et al. 2000) provided evidence that in hepatic tissue metformin inhibited mitochondria complex 1 and, in turn, the increase in AMP activated as a result lowered the ATP to AMP ratio and, in turn, the increase in AMP activated AMPK.”
BackgroundClinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318 · cited 1×
“Metformin does accumulate in erythrocytes and enterocytes and accumulation in the latter is a contribution to the absorption-limited pharmacokinetics observed with higher doses of metformin (Tucker et al. 1981, Scheen 1996, Kinaan et al. 2015).”
BackgroundMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284 · cited 4×
“The data presented by Madiraju et al. (2014) indicate that a more likely mitochondria target is mitochondrial glycerophosphate dehydrogenase that metformin inhibits with a Ki of 55 lM.”
BackgroundInfluentialForetz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., & Viollet, B. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40671 · Cited by 1,181 · cited 5×
“An incorrect citation to the study by Tucker et al. (1981) has inferred a plasma half-life of 20 h; however, this longer estimate of half-life reflects a slow phase of urinary excretion of 19 h (Fortez et al. 2014).”
BackgroundInfluentialCalorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS
Nisoli, E., Tonello, C., Cardile, A., Cozzi, V., Bracale, R., Tedesco, L., Falcone, S., Valerio, A., Cantoni, O., Clementi, E., et al. (2005) · Science · doi:10.1126/science.1117728 · Cited by 1,107 · cited 2×
“…feedback whereby NO enhances the expression of SIRT1 mRNA and the protein sirtuin 1 via the SIRT1 promoter has been reported in calorie restricted mice; these changes were accompanied by an increase in the biogenesis of mitochondria, but were absent in eNOS deficient mice (Nisoli et al. 2005).”
BackgroundAMPK and SIRT1: a long-standing partnership?
Ruderman, N. B., Julia Xu, X., Nelson, L., Cacicedo, J. M., Saha, A. K., Lan, F., & Ido, Y. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00745.2009 · Cited by 903 · cited 1×
“…a strong evolutionary link between SIRT1 and AMPK as regulators of metabolism with substantial evidence emphasizing the importance of AMPK and SIRT1 as targets for the prevention and treatment of disorders such as diabetes and cardiovascular disease (Ruderman et al. 2010, Dolinsky & Dyck 2011).”
BackgroundMattagajasingh, I., Kim, C.-S., Naqvi, A., Yamamori, T., Hoffman, T. A., Jung, S.-B., DeRicco, J., Kasuno, K., & Irani, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704329104 · Cited by 881
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“…the putative anticancer effects of metformin seem to be more effective against certain types of cancer, notably breast and lung cancer, inferring that metformin may preferentially target a cellular pathway(s) that are specific for certain cancers (Jiralerspong et al. 2009, Tan et al. 2011).”
BackgroundSIRT1 Modulation of the Acetylation Status, Cytosolic Localization, and Activity of LKB1
Lan, F., Cacicedo, J. M., Ruderman, N., & Ido, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805711200 · Cited by 825
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786 · cited 2×
“Metformin is also used for the treatment of polycystic ovary syndrome (Lord et al. 2003); nonalcoholic fatty liver disease (NAFLD) (Marchesini et al.”
BackgroundMetformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Kawano, H., Motoyama, T., Hirashima, O., Hirai, N., Miyao, Y., Sakamoto, T., Kugiyama, K., Ogawa, H., & Yasue, H. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00168-0 · Cited by 676 · cited 1×
“Related to these studies from Kawano et al. (1999) and Ihlemann et al. (2003), it is of particular interest that Zhang et al. (2013) have reported that a single 500 mg dose of metformin prevents the reduction of brachial artery FMD following an oral glucose load in patients with primary…”
BackgroundMetformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567 · cited 1×
“…evidence as to the cellular mechanisms of action of metformin for the antihyperglycaemic effects of metformin to the activation of AMPK, not all of the experimental evidence is supportive (Rena et al. 2013, Rojas & Gomes 2013, Fortez et al. 2014, Pernicova & Korbonits 2014, Kinaan et al. 2015).”
BackgroundImproved Endothelial Function With Metformin in Type 2 Diabetes Mellitus
Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01129-9 · Cited by 513
Molecular mechanism of action of metformin: old or new insights?
Rena, G., Pearson, E. R., & Sakamoto, K. (2013) · Diabetologia · doi:10.1007/s00125-013-2991-0 · Cited by 479
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441 · cited 1×
“Polymorphisms in OCTs have been linked to the variability in the clinical effectiveness as well as the toxicity of metformin (Wang et al. 2003, Shu et al. 2008, Yue et al. 2008, Graham et al. 2011).”
BackgroundUse of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency
Lipska, K. J., Bailey, C. J., & Inzucchi, S. E. (2011) · Diabetes Care · doi:10.2337/dc10-2361 · Cited by 432
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428 · cited 3×
“For instance, Franciosi et al. (2013) conducted a systematic review of data from 12 randomized controlled trials and 41 observational studies, and although the analysis of a reduction in risk was apparent based on the observational studies, this was not supported by analysis of data from the…”
BackgroundMethodJohnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Accumulation of Metformin by Tissues of the Normal and Diabetic Mouse
Wilcock, C., & Bailey, C. J. (1994) · Xenobiotica · doi:10.3109/00498259409043220 · Cited by 418 · cited 2×
“Steady-state plasma concentrations of metformin during clinical use are reported to be in the range of 1–10 lM with potentially higher concentrations of 50 lM in the hepatic circulation (Tucker et al. 1981, Wilcock et al. 1991, Wilcock & Bailey 1994, Bailey & Turner 1996).”
BackgroundMethodCaporali, A., Meloni, M., Völlenkle, C., Bonci, D., Sala-Newby, G. B., Addis, R., Spinetti, G., Losa, S., Masson, R., Baker, A. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.952325 · Cited by 397
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.21.2594 · Cited by 312
Zu, Y., Liu, L., Lee, M. Y. K., Xu, C., Liang, Y., Man, R. Y., Vanhoutte, P. M., & Wang, Y. (2010) · Circulation Research · doi:10.1161/circresaha.109.215483 · Cited by 303
Activation and Signaling by the AMP-Activated Protein Kinase in Endothelial Cells
Fisslthaler, B., & Fleming, I. (2009) · Circulation Research · doi:10.1161/circresaha.109.201590 · Cited by 295
The AMPK Inhibitor Compound C Is a Potent AMPK-Independent Antiglioma Agent
Liu, X., Chhipa, R. R., Nakano, I., & Dasgupta, B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0579 · Cited by 288 · cited 1×
“…C (dorsomorphin) and/or the AMP-mimic and AMPK activator, AICAR; however, there is substantive evidence that these kinase modulators are not specific for AMPK thus raising the likelihood that other cellular pathways may be involved in mediating the effects of metformin (Liu et al. 2014a,b).”
BackgroundAMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633
Chen, Z., Peng, I.-C., Sun, W., Su, M.-I., Hsu, P.-H., Fu, Y., Zhu, Y., DeFea, K., Pan, S., Tsai, M.-D., et al. (2009) · Circulation Research · doi:10.1161/circresaha.108.187567 · Cited by 264 · cited 1×
“Published by John Wiley & Sons Ltd, doi: 10.1111/apha.12644 143 Ser1177 and Ser633 and enhances the generation of NO (Chen et al. 1999, 2009).”
BackgroundInfluentialDetaille, D., Guigas, B., Chauvin, C., Batandier, C., Fontaine, E., Wiernsperger, N., & Leverve, X. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2179 · Cited by 263 · cited 1×
“…effects, improved contribution of NO to EDV, effects on calcium handling, inhibition of mitochondrial complex 1 and activation of AMPK, and inhibition of apoptosis (Bhalla & Sharma 1996, Faure et al. 1999, Katakam et al. 2000, Zhou et al. 2001, Detaille et al. 2005, Arunachalam et al. 2014a).”
BackgroundMetformin modulates hyperglycaemia‐induced endothelial senescence and apoptosis through SIRT1
Arunachalam, G., Samuel, S. M., Marei, I., Ding, H., & Triggle, C. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12496 · Cited by 221
Self-citationFaure, P., Rossini, E., Wiernsperger, N., Richard, M. J., Favier, A., & Halimi, S. (1999) · Diabetes · doi:10.2337/diabetes.48.2.353 · Cited by 166 · cited 1×
“…effects, improved contribution of NO to EDV, effects on calcium handling, inhibition of mitochondrial complex 1 and activation of AMPK, and inhibition of apoptosis (Bhalla & Sharma 1996, Faure et al. 1999, Katakam et al. 2000, Zhou et al. 2001, Detaille et al. 2005, Arunachalam et al. 2014a).”
BackgroundMetformin improves endothelial function in patients with metabolic syndrome
VITALE, C., MERCURO, G., CORNOLDI, A., FINI, M., VOLTERRANI, M., & ROSANO, G. M. C. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01531.x · Cited by 164
Ihlemann, N., Rask-Madsen, C., Perner, A., Dominguez, H., Hermann, T., Køber, L., & Torp-Pedersen, C. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00008.2003 · Cited by 113 · cited 3×
“In a comparable study, Ihlemann et al. (2003) used venous occlusion plethysmography to assess forearm blood flow before and after an oral glucose challenge and found that intra-arterial infusion of serotonin-induced EDV was reduced; however, the presence of the eNOS co-factor,…”
BackgroundResultSubcellular Distribution of Metformin in Rat Liver
Wilcock, C., Wyre, N. D., & Bailey, C. J. (1991) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1991.tb03507.x · Cited by 86 · cited 2×
“Steady-state plasma concentrations of metformin during clinical use are reported to be in the range of 1–10 lM with potentially higher concentrations of 50 lM in the hepatic circulation (Tucker et al. 1981, Wilcock et al. 1991, Wilcock & Bailey 1994, Bailey & Turner 1996).”
BackgroundMetformin-Treated Patients With Type 2 Diabetes Have Normal Mitochondrial Complex I Respiration
Larsen, S., Rabøl, R., Hansen, C. N., Madsbad, S., Helge, J. W., & Dela, F. (2012) · Diabetologia · doi:10.1007/s00125-011-2340-0 · Cited by 81 · cited 2×
“respiration in their skeletal muscle (Larsen et al. 2012).”
BackgroundInfluentialBhalla, R. (1996) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00356-8 · Cited by 68
Ghosh, S., Lakshmanan, A. P., Hwang, M. J., Kubba, H., Mushannen, A., Triggle, C. R., & Ding, H. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.10.008 · Cited by 45
Self-citation
Research works printed but not linked: 80
- Allen, 1960, Dimethyl biguanidine dans le traitement du diabete sucre, Rev Francaise d'Endocrinol Clin, 2, 1
- Arunachalam, 2010, SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol, Biochem Biophys Res Commun, 393, 66, 10.1016/j.bbrc.2010.01.080 · DOI · Paper page
- Arunachalam, 2014b, Micro RNA-34a mediates impaired angiogenesis in diabetes: Role of SIRT1 and metformin, FASEB J, 28, 1051.2, 10.1096/fasebj.28.1_supplement.1051.2 · DOI
- Arunachalam, 2015a, MicroRNA signature and cardiovascular dysfunction, J Cardiovasc Pharmacol, 65, 419, 10.1097/FJC.0000000000000178 · DOI
- Arunachalam, 2015b, Molecular interplay between microRNA-34a and sirtuin1 in hyperglycaemia-mediated impaired angiogenesis in endothelial cells: Effects of metformin, J Pharmacol Exp Ther
- Badrick, 2014, Diabetes and cancer: 5 years into the recent controversy, Eur J Cancer, 50, 2119, 10.1016/j.ejca.2014.04.032 · DOI · Paper page
- Bailey, 2004, Metformin: its botanical background, Pract Diabetes Int, 21, 115, 10.1002/pdi.606 · DOI · Paper page
- Ben Sahra, 2010, The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells, Autophagy, 6, 670, 10.4161/auto.6.5.12434 · DOI · Paper page
- Berkowitz, 2014, Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study, JAMA Intern Med, 174, 1955, 10.1001/jamainternmed.2014.5294 · DOI · Paper page
- Blandino, 2012, Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC, Nat Commun, 29, 865, 10.1038/ncomms1859 · DOI · Paper page
- Bommer, 2007, p53-mediated activation of miRNA34 candidate tumor-suppressor genes, Curr Biol, 17, 1298, 10.1016/j.cub.2007.06.068 · DOI · Paper page
- Bordone, 2005, Calorie restriction, SIRT1 and metabolism: understanding longevity, Nat Rev Mol Cell Biol, 6, 298, 10.1038/nrm1616 · DOI · Paper page
- Brownlee, 2001, Biochemisty and molecular cell biology of diabetic complications, Nature, 414, 813, 10.1038/414813a · DOI · Paper page
- Chang, 2002, Regulation of lifespan by histone deacetylase, Ageing Res Rev, 1, 313, 10.1016/S1568-1637(02)00003-X · DOI · Paper page
- Cheang, 2014, Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5′ adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway, Arterioscler Thromb Vasc Biol, 34, 830, 10.1161/ATVBAHA.113.301938 · DOI · Paper page
- Chen, 1999, AMP-activated protein kinase phosphorylation of endothelial NO synthase, FEBS Lett, 443, 285, 10.1016/S0014-5793(98)01705-0 · DOI · Paper page
- Chen, 2010, Shear stress, SIRT1, and vascular homeostasis, Proc NatL Acad Sci USA, 107, 10268, 10.1073/pnas.1003833107 · DOI · Paper page
- Davis, 2006, Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase, Diabetes, 55, 496, 10.2337/diabetes.55.02.06.db05-1064 · DOI · Paper page
- Deichmann, 1986, What is there that is not poison? A study of the Third Defense by Paracelsus, Arch Toxicol, 58, 207, 10.1007/BF00297107 · DOI
- Diabetes Control and Complications Trial Research Group, 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 · DOI · Paper page
- Ding, 2010, Endothelial dysfunction in diabetes: multiple targets for treatment, Pflugers Arch, 459, 977, 10.1007/s00424-010-0807-3 · DOI
- Dobrina, 1983, Metabolic properties of freshly isolated bovine endothelial cells, Biochim Biophys Acta, 762, 295, 10.1016/0167-4889(83)90084-8 · DOI
- Dolinsky, 2011, Calorie restriction and resveratrol in cardiovascular health and disease, Biochim Biophys Acta, 1812, 1477, 10.1016/j.bbadis.2011.06.010 · DOI · Paper page
- Dumortier, 2013, MicroRNAs and metabolism crosstalk in energy homeostasis, Cell Metab, 18, 312, 10.1016/j.cmet.2013.06.004 · DOI · Paper page
- Enkhjargal, 2014, Endothelial AMP-activated protein kinase regulates blood pressure and coronary flow responses through hyperpolarization mechanism in mice, Arterioscler Thromb Vasc Biol, 34, 1505, 10.1161/ATVBAHA.114.303735 · DOI
- Faubert, 2013, AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo, Cell Metab, 17, 113, 10.1016/j.cmet.2012.12.001 · DOI · Paper page
- Grundy, 2003, Prevention conference VI: diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association, Circulation, 105, 2231, 10.1161/01.CIR.0000013952.86046.DD · DOI · Paper page
- Hadden, 2005, Goat's rue - French lilac - Italian fitch -Spanish sainfoin: gallega officinalis and metformin: The Edinburgh connection, J R Coll Physicians Edinb, 35, 258, 10.1177/1478271520053503010 · DOI
- Hemmingsen, 2012, Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses, BMJ, 344, e1771, 10.1136/bmj.e1771 · DOI · Paper page
- Herzig, 2001, CREB regulates hepatic gluconeogenesis through the coactivator PGC-1, Nature, 413, 179, 10.1038/35093131 · DOI · Paper page
- Hou, 2010, Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway, Biochem Biophys Res Commun, 396, 199, 10.1016/j.bbrc.2010.04.017 · DOI · Paper page
- Ibáñez, 2006, Metformin treatment to prevent early puberty in girls with precocious pubarche, J Clin Endocrinol Metab, 91, 2888, 10.1210/jc.2006-0336 · DOI · Paper page
- Ito, 2010, MicroRNA-34a regulation of endothelial senescence, Biochem Biophys Res Commun, 398, 735, 10.1016/j.bbrc.2010.07.012 · DOI · Paper page
- Jansson, 1996, The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM, Diabetes Care, 19, 160, 10.2337/diacare.19.2.160 · DOI · Paper page
- Katakam, 2000, Metformin improves vascular function in insulin-resistant rats, Hypertension, 35, 108, 10.1161/01.HYP.35.1.108 · DOI · Paper page
- Kato, 2015, Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor, Biochem Biophys Res Commun, 461, 115, 10.1016/j.bbrc.2015.03.178 · DOI
- Kim, 2008, SIRT1: roles in ageing and cancer, BMB Rep, 41, 751, 10.5483/BMBRep.2008.41.11.751 · DOI · Paper page
- Langman, 2006, Toxicology: then and now, Clin Biochem, 39, 498, 10.1016/j.clinbiochem.2006.03.004 · DOI
- Lee, 2010, AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner, J Biol Chem, 285, 32182, 10.1074/jbc.M110.134890 · DOI · Paper page
- Lin, 2014, Ghrelin receptor regulates appetite and satiety during aging in mice by regulating meal frequency and portion size but not total food intake, J Nutr, 144, 1349, 10.3945/jn.114.191171 · DOI
- Liu, 2014a, Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK, Proc Natl Acad Sci U S A, 111, E435, 10.1073/pnas.1311121111 · DOI · Paper page
- Ludvigsson, 2014, The latest pharmacotherapy options for type 1 diabetes, Expert Opin Pharmacother, 15, 37, 10.1517/14656566.2014.855197 · DOI
- Marfella, 1996, Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients, Diabetes Care, 9, 934, 10.2337/diacare.19.9.934 · DOI · Paper page
- Memmott, 2010, Metformin prevents tobacco carcinogen-induced lung tumorigenesis, Cancer Prev Res (Phila), 3, 1066, 10.1158/1940-6207.CAPR-10-0055 · DOI · Paper page
- Ota, 2007, Sirt1 modulates premature senescence-like phenotype in human endothelial cells, J Mol Cell Cardiol, 43, 571, 10.1016/j.yjmcc.2007.08.008 · DOI · Paper page
- Ota, 2008, Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells, Arterioscler Thromb Vasc Biol, 28, 1634, 10.1161/ATVBAHA.108.164368 · DOI · Paper page
- Ouchi, 2005, AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle, Circ Res, 96, 838, 10.1161/01.RES.0000163633.10240.3b · DOI · Paper page
- Pernicova, 2014, Metformin-mode of action and clinical implications for diabetes and cancer, Nat Rev Endocrinol, 10, 143, 10.1038/nrendo.2013.256 · DOI · Paper page
- Potente, 2008, NO targets SIRT1: a novel signaling network in endothelial senescence, Arterioscler Thromb Vasc Biol, 28, 1577, 10.1161/ATVBAHA.108.173682 · DOI
- Qin, 2012, Role of microRNAs in endothelial inflammation and senescence, Mol Biol Rep, 39, 4509, 10.1007/s11033-011-1241-0 · DOI
- Rocha, 2011, Metformin amplifies chemotherapy-induced AMPK-activation and antitumoral growth, Clin Cancer Res, 17, 3993, 10.1158/1078-0432.CCR-10-2243 · DOI · Paper page
- Sakamoto, 2006, Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1, Am J Physiol Endocrinol Metab, 290, E780, 10.1152/ajpendo.00443.2005 · DOI · Paper page
- Salpeter, 2003, Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus, Cochrane Database Syst Rev, 2, CD002967
- Sambol, 1996, Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus, J Clin Pharmacol, 36, 1012, 10.1177/009127009603601105 · DOI · Paper page
- Schäfer, 1980, Guanidines and biguanides, Pharmacol Ther, 8, 275, 10.1016/0163-7258(80)90049-2 · DOI
- Scheen, 1996, Clinical pharmacokinetics of metformin, Clin Pharmacokinet, 30, 359, 10.2165/00003088-199630050-00003 · DOI · Paper page
- Shu, 2008, Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics, Clin Pharmacol Ther, 83, 273, 10.1038/sj.clpt.6100275 · DOI · Paper page
- Sirtoli, 1978, Dispositin of metformin (NN-dimethylbiguanide) in man, Clin Pharmacol Ther, 24, 683, 10.1002/cpt1978246683 · DOI · Paper page
- Stein, 2010, SIRT1 reduces endothelial activation without affecting vascular function in ApoE−/− mice, Aging (Albany, NY), 2, 353, 10.18632/aging.100162 · DOI · Paper page
- Sterne, 1957, Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanide (N.N.D.G.), Maroc Med, 36, 1295
- Suarez, 2009, MicroRNAs as novel regulators of angiogenesis, Circ Res, 104, 442, 10.1161/CIRCRESAHA.108.191270 · DOI · Paper page
- Suissa, 2012, Metformin and the risk of cancer: time-related biases in observational studies, Diabetes Care, 35, 2665, 10.2337/dc12-0788 · DOI · Paper page
- Tabuchi, 2012, MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression, Clin Sci (Lond), 123, 161, 10.1042/CS20110563 · DOI · Paper page
- Tan, 2011, Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes, Cancer, 117, 5103, 10.1002/cncr.26151 · DOI · Paper page
- Towler, 2007, AMP-activated protein kinase in metabolic control and insulin signaling, Circ Res, 100, 328, 10.1161/01.RES.0000256090.42690.05 · DOI · Paper page
- Triggle, 2010, A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS, J Am Soc Hypertens, 4, 102, 10.1016/j.jash.2010.02.004 · DOI
- Triggle, 2014, Cardiovascular impact of drugs used in the treatment of diabetes, Ther Adv Chronic Dis, 5, 245, 10.1177/2040622314546125 · DOI · Paper page
- Triggle, 2014, Metformin: Targets SIRT1 and microRNAs in microvascular endothelial cells, J Vasc Res, 51, 37
- Tucker, 1981, Metformin kinetics in healthy subjects and in patients with diabetes mellitus, Br J Clin Pharmacol, 12, 235, 10.1111/j.1365-2125.1981.tb01206.x · DOI · Paper page
- Werner, 1921, The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively, J Chem Soc Trans, 121, 1790, 10.1039/CT9222101790 · DOI · Paper page
- Wu, 2012, Activation of the AMP-activated protein kinase by eicosapentaenoic acid (EPA, 20:5 n-3) improves endothelial function in vivo, PLoS One, 7, e35508, 10.1371/journal.pone.0035508 · DOI · Paper page
- Xu, 2005, Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex, Am J Physiol, 289, F1040
- Yamakuchi, 2008, miR-34a repression of SIRT1 regulates apoptosis, Proc Natl Acad Sci U S A, 105, 13421, 10.1073/pnas.0801613105 · DOI · Paper page
- Yue, 2008, Effect of genetic variation in the organic cation transporter, Clin Pharmacol Ther, 83, 273, 10.1038/sj.clpt.6100275 · DOI · Paper page
- Yun, 2005, Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma, J Biol Chem, 280, 9963, 10.1074/jbc.M412994200 · DOI · Paper page
- Zampetaki, 2012, MicroRNAs in vascular and metabolic disease, Circ Res, 110, 508, 10.1161/CIRCRESAHA.111.247445 · DOI · Paper page
- Zhang, 2000, High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells, J Biol Chem, 275, 40042, 10.1074/jbc.M007505200 · DOI · Paper page
- Zhang, 2013, Metformin reduces vascular endothelial dysfunction caused by an acute glucose load in patients with hypertension, Blood Press, 22, 106, 10.3109/08037051.2012.732761 · DOI
- Zhou, 2001, Role of AMP-activated protein kinase in mechanism of metformin action, J Clin Invest, 108, 1167, 10.1172/JCI13505 · DOI · Paper page
- Zhu, 2015, Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies, Diabetologia, 58, 900, 10.1007/s00125-015-3510-2 · DOI · Paper page
Cited by
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,142
Anti-senescence compounds: A potential nutraceutical approach to healthy aging
Gurău, F., Baldoni, S., Prattichizzo, F., Espinosa, E., Amenta, F., Procopio, A. D., Albertini, M. C., Bonafè, M., & Olivieri, F. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.001 · Cited by 179
Challenges and Perspectives in the Treatment of Diabetes Associated Breast Cancer
Samuel, S. M., Varghese, E., Varghese, S., & Büsselberg, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.08.004 · Cited by 141
Endothelial Function and Dysfunction: Impact of Metformin
Nafisa, A., Gray, S. G., Cao, Y., Wang, T., Xu, S., Wattoo, F. H., Barras, M., Cohen, N., Kamato, D., & Little, P. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.07.007 · Cited by 128
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects
Salvatore, T., Pafundi, P. C., Galiero, R., Rinaldi, L., Caturano, A., Vetrano, E., Aprea, C., Albanese, G., Di Martino, A., Ricozzi, C., et al. (2020) · Biomedicines · doi:10.3390/biomedicines9010003 · Cited by 97
Metadata
- Authors
- Triggle, C. R., & Ding, H.
- Venue
- Acta Physiologica
- Publisher
- Wiley
- Published
- 2016-01-13
- Volume
- 219
- Issue
- 1
- Pages
- 138-151
- ISSN
- 1748-1708 (ISSN-L)
- OpenAlex
- W2217461794
- Cited by
- 100
- References
- 46
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1 (tdm)
- onlinelibrary.wiley.com/termsAndConditions (vor)
- Funders
- NPRP (4-910-3-244, 5-149-3-040)
- Qatar National Research Fund
- Qatar Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.